作者
Dominik Bettenworth,Mark E. Baker,Joel G. Fletcher,Vipul Jairath,Cathy Lu,Willem A. Bemelman,Geert d’Haens,André D’Hoore,Axel Dignaß,Iris Dotan,Roger Feakins,Phillip Fleshner,Christina Ha,G.T. Henderson,Ruishen Lyu,Julián Panés,Gerhard Rogler,Ren Mao,Jordi Rimola,William J. Sandborn,Siew C. Ng,Britta Siegmund,Mark S. Silverberg,Stuart A. Taylor,Bram Verstockt,Ilyssa O. Gordon,David H. Bruining,Brian G. Feagan,Florian Rieder
摘要
Fibrostenosis of the small bowel is common in patients with Crohn's disease. No consensus recommendations on definition, diagnosis and management in clinical practice are currently available. In this Consensus Statement, we present a clinical practice RAND/UCLA appropriateness study on the definition, diagnosis and clinical management of fibrostenosing Crohn's disease. It was conducted by a panel of 28 global experts and one patient representative. Following a systematic literature review, 526 candidate items grouped into 136 questions were generated and subsequently evaluated for appropriateness. Strictures are best defined as wall thickening, luminal narrowing and prestenotic dilation. Cross-sectional imaging is required for accurate diagnosis of fibrostenosing Crohn's disease, and it is recommended before making treatment decisions. It should also assess the degree of inflammation in the bowel wall. Multiple options for medical anti-inflammatory, endoscopic and surgical therapies were suggested, including follow-up strategies following therapy. This Consensus Statement supports clinical practice through providing guidance on definitions, diagnosis and therapeutic management of patients with fibrostenosing small bowel Crohn's disease. In this Consensus Statement, a global multidisciplinary panel of experts provides recommendations for the definitions, diagnosis and management of patients with fibrostenosing small bowel Crohn's disease.